Corona Remedies Ltd

- There is no mention of any current or future fundraising through debt or equity in the provided transcript. - The company states that it is largely a net cash company with minimal borrowings. - Borrowings mainly consist of overdraft facilities linked to fixed deposits, amounting to INR 143 crores in FY26, with no traditional bank cash credit facility in use. - There was a long-term loan of INR 16 crores from Myoril, expected to be paid off within the year. - No indication or discussion about plans for raising new debt or equity capital was given during the call. - The company emphasized strong cash flow generation and internal accruals to support operations and expansion plans.

- Expansion of manufacturing capabilities with the addition of a new 600-kg production line. - Commissioning of a dedicated hormone manufacturing plant expected to be operational in Q1 or Q2 of FY27. - Receipt of EAEU GMP certification enabling expansion into key Eurasian markets (Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan). - These investments aim to strengthen manufacturing backbone, improve scalability, and support growth in domestic and international business. - Strategic acquisitions completed in FY26 include the Bayers Portfolio and Wokadine (ranked 2 in Indian Povidone Iodine market). - Entry into the biosimilars and biologics market with launch of three biosimilar products to build a platform for future innovation and growth. These capital expenditures and investments focus on enhancing production capacity, expanding market reach, and diversifying product offerings aligned with long-term growth strategy.

- Anticipated overall IPM growth for FY27 is about 10% to 10.3%, with volume growth expected at 1.5% to 2%; rest driven by price and new launches. - CORONA Remedies expects to outperform the market volume growth by about 3x to 4x through added medical representatives and restructuring of divisions, including launching new products like Wokadine. - Committed to 15% organic revenue growth domestically and 25% growth in the acquired portfolio, targeting 20%+ PAT growth in FY27. - International business projected to grow at high single digits (8-9%) over next 3-4 years, contributing about 4-5% of overall revenue. - Focus on sustained double-digit growth in the IPM over the next year, expected to be volume-driven and supported by product launches and improved salesforce productivity.

- CORONA Remedies Limited targets a revenue growth of 15% organically and 25% from the acquired portfolio in FY27. - Profit After Tax (PAT) is expected to grow by over 20% in FY27. - EBITDA margins improved to 20.9% in FY26 with expectations of further operational effectiveness driving margin expansion in coming years. - Volume growth for FY27 is anticipated at 3x to 4x vs market volume growth of 1.5% to 2%, supported by increased medical representative strength and new product launches. - Sustained gross margins around 80% are expected despite inflationary pressures, due to a strong mix of non-NLEM products and price revision levers. - The company aims to maintain 15% revenue growth and 20% PAT growth over the next 3-5 years. - Return ratios for FY26 were robust with RoCE ~41% and RoE ~29.2%, underpinning profitability expectations.

The transcript from CORONA Remedies Limited's earnings call does not provide specific details about the current or expected order book or pending orders. The discussion primarily revolves around revenue growth, market expansion (domestic and international), margin outlook, sales force productivity, and product launches. Key takeaways related to business outlook: - Anticipated overall IPM (Indian Pharma Market) growth of around 10% to 10.3% for FY '27. - Company targeting 15% organic revenue growth and 25% growth from acquired portfolios. - International business forecasted to grow at a high single-digit rate (~8-9%) over the next 3-4 years. - Volume growth expected to accelerate 3x to 4x for the company. - No mention of exact pending orders or order book figures.